VivoSeq
Oncology

Myeloid Leukemia

86

Pipeline Programs↗

27

Active Trials↗

39

Companies Involved↗

Myeloid Leukemia is a moderately active landscape with 86 programs across 39 companies. The most active players are Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Enliven Therapeutics, Crossbow Therapeutics, Inc.. 9 therapies are approved with 9 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

69/100

Pipeline Velocity

22/100

Mech. Concentration

12/100

Completion Rate

69/100

Attrition Rate

20/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. logo

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

1 program

Phase 1E

Enliven Therapeutics

1 program

Phase 1C

Crossbow Therapeutics, Inc.

1 program

Phase 1Chong Kun Dang Pharmaceutical logo

Chong Kun Dang Pharmaceutical

1 program

Phase 1Jiangsu Hansoh Pharmaceutical Co., Ltd. logo

Jiangsu Hansoh Pharmaceutical Co., Ltd.

4 programs

Phase 1Teva logo

Teva

2 programs

Phase 2

Pipeline

Programs by Phase

Preclinical9

Gemtuzumab Ozogamicin

Wyeth-Lederle Vaccines

Flumatinib

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Armodafinil

Nuvo Research GmbH

AMN107

Novartis

Flumatinib Mesylate

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Phase 119

Nivolumab

Bristol-Myers Squibb

Filgrastim

Eastern Cooperative Oncology Group

Azacitidine

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Axitinib

Prism Pharmaceuticals

Ipilimumab

Bristol-Myers Squibb

Phase 240

Pembrolizumab

Merck & Co.

Mitoxantrone Hydrochloride

Pfizer

Cytarabine

Teva

Pioglitazone

Takeda

Idarubicin

Pfizer

Phase 39

Gilteritinib

Astellas

Cyclophosphamide

Baxter Healthcare Corporation

Methotrexate

Alnylam Pharmaceuticals

Ponatinib

Takeda

Busulfan

Akero Therapeutics

Approved9

Decitabine

Sun Pharma

Venetoclax

AbbVie

Nilotinib

Azurity Pharmaceuticals

Bosutinib

Prism Pharmaceuticals

Mitoxantrone

EMD Serono

Analysis

Modality Breakdown

79%

Small molecule

77 of 97 classified programs — the dominant modality here.

21%ALL OTHERSProtein / enzyme99%Monoclonal antibody33%Cell therapy33%Gene therapy22%Vaccine22%Antibody–drug conjugate11%

Small molecule leads; the ring shows all 97 classified programs, each share of the total. Modality classified for 100% of 101 pipeline programs.

Analysis

Trial Status

161

clinical trials

Completed74 · 46%
Terminated28 · 17%
Unknown status24 · 15%
Recruiting15 · 9%
Active, not recruiting6 · 4%
Not yet recruiting5 · 3%
Other9 · 6%

Clinical Trials

Trial Activity

161 trials

EPIgenetics and in Vivo Resistance of Chronic Myeloid Leukemia Stem Cells to Tyrosine Kinase Inhibitors
Recruiting·UUniversity Hospital, Clermont-Ferrand·N/A·NCT03481868·160 enrolled
ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese Participants
Recruiting·EEnliven Therapeutics·Phase 1·NCT06787144·21 enrolled
A Study of HS-10382 in Patients With Chronic Myeloid Leukemia.
Recruiting·Jiangsu Hansoh Pharmaceutical Co., Ltd. logoJiangsu Hansoh Pharmaceutical Co., Ltd.·Phase 1·NCT05367700·108 enrolled
A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia
Recruiting·EEnliven Therapeutics·Phase 1·NCT05304377·200 enrolled
Discontinuation of TyrosIne Kinase Inhibitors (TKI) in Chronic Myeloid Leukemia (CML) and Impact on the Immune System
Recruiting·PPoitiers University Hospital·Phase 3·NCT05753384·140 enrolled
Phase II Study of Asciminib for Second-line Treatment of Chronic Phase Chronic Myeloid Leukemia
Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT06629584·40 enrolled
Efficacy and Safety of Generic Imatinib (Carcemia®) Compared to Glivec® in Real-Life Management of Chronic Phase of Chronic Myeloid Leukemia
Recruiting·HHikma Pharmaceuticals LLC·N/A·NCT05282108·240 enrolled
ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase
Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT05007873·70 enrolled
Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT06817720·50 enrolled
A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias
Recruiting·CCrossbow Therapeutics, Inc.·Phase 1·NCT06994676·72 enrolled
Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.
Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT06236724·50 enrolled
Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib
Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT01746836·50 enrolled
A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL)
Recruiting·TTerns, Inc.·Phase 1/2·NCT06163430·180 enrolled
KRT-232 and TKI Study in Chronic Myeloid Leukemia
Recruiting·KKartos Therapeutics, Inc.·Phase 1/2·NCT04835584·109 enrolled
Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation
Recruiting·MMedical College of Wisconsin·Phase 2·NCT04838041·51 enrolled
Page 1 of 11

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)